Zacks Research Issues Pessimistic Estimate for JNJ Earnings

Johnson & Johnson (NYSE:JNJ - Free Report) - Stock analysts at Zacks Research lowered their Q1 2025 earnings per share estimates for Johnson & Johnson in a research note issued to investors on Wednesday, February 12th. Zacks Research analyst K. Shah now expects that the company will earn $2.60 per share for the quarter, down from their prior forecast of $2.63. The consensus estimate for Johnson & Johnson's current full-year earnings is $10.58 per share. Zacks Research also issued estimates for Johnson & Johnson's Q3 2025 earnings at $2.78 EPS, Q4 2025 earnings at $2.48 EPS, FY2025 earnings at $10.55 EPS, Q1 2026 earnings at $2.66 EPS, Q2 2026 earnings at $2.76 EPS, Q3 2026 earnings at $2.79 EPS, Q4 2026 earnings at $2.83 EPS and FY2027 earnings at $11.48 EPS.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business's revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the company earned $2.29 EPS.

A number of other equities research analysts have also recently commented on the company. Raymond James dropped their target price on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating on the stock in a research report on Thursday, January 23rd. Citigroup cut their price objective on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a research report on Wednesday, December 11th. Argus upgraded Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Royal Bank of Canada reissued an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Thursday, January 23rd. Finally, StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 25th. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson currently has an average rating of "Moderate Buy" and an average price target of $170.67.

Johnson & Johnson Stock Performance

JNJ stock traded down $0.08 during midday trading on Friday, hitting $154.83. 2,361,828 shares of the stock traded hands, compared to its average volume of 8,811,842. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The stock's fifty day simple moving average is $148.00 and its 200-day simple moving average is $155.91. The firm has a market cap of $372.78 billion, a P/E ratio of 23.30, a PEG ratio of 2.46 and a beta of 0.52.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.20%. Johnson & Johnson's dividend payout ratio is presently 74.59%.

Insider Activity

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the firm's stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company's stock, valued at approximately $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.16% of the company's stock.

Hedge Funds Weigh In On Johnson & Johnson

Large investors have recently modified their holdings of the business. Vinva Investment Management Ltd boosted its stake in Johnson & Johnson by 6.8% during the third quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company's stock worth $17,988,000 after buying an additional 7,110 shares during the period. Financial Counselors Inc. boosted its position in shares of Johnson & Johnson by 5.3% during the 3rd quarter. Financial Counselors Inc. now owns 185,093 shares of the company's stock worth $29,996,000 after purchasing an additional 9,309 shares during the period. Oregon Pacific Wealth Management LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at approximately $949,000. Meridian Investment Counsel Inc. raised its position in Johnson & Johnson by 19.6% in the third quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company's stock valued at $3,667,000 after purchasing an additional 3,710 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in Johnson & Johnson by 0.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company's stock worth $2,858,543,000 after purchasing an additional 102,502 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.